1.1 Eribulin is recommended as an option for treating locally advanced or metastatic breast cancer in adults, only when:
it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine)
the company provides eribulin with the discount agreed in the patient access scheme.
1.2 This guidance is not intended to affect the position of patients whose treatment with eribulin was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.